KalVista Pharmaceuticals (STU:4XC1) EBIT per Share : €-3.30 (TTM As of Jan. 2024)

View and export this data going back to 2016. Start your Free Trial

What is KalVista Pharmaceuticals EBIT per Share?

KalVista Pharmaceuticals's EBIT per Share for the three months ended in Jan. 2024 was €-0.88. Its EBIT per Share for the trailing twelve months (TTM) ended in Jan. 2024 was €-3.30.

During the past 3 years, the average EBIT per Share Growth Rate was -20.30% per year. During the past 5 years, the average EBIT per Share Growth Rate was -19.70% per year. During the past 10 years, the average EBIT per Share Growth Rate was 16.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for KalVista Pharmaceuticals's EBIT per Share or its related term are showing as below:

STU:4XC1' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -130 Med: -18.7 Max: 61.1
Current: -20.3

During the past 12 years, the highest 3-Year average EBIT per Share Growth Rate of KalVista Pharmaceuticals was 61.10% per year. The lowest was -130.00% per year. And the median was -18.70% per year.

STU:4XC1's 3-Year EBIT Growth Rate is ranked worse than
74.33% of 1305 companies
in the Biotechnology industry
Industry Median: 3.4 vs STU:4XC1: -20.30

KalVista Pharmaceuticals's EBIT for the three months ended in Jan. 2024 was €-30.43 Mil.

KalVista Pharmaceuticals EBIT per Share Historical Data

The historical data trend for KalVista Pharmaceuticals's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

KalVista Pharmaceuticals EBIT per Share Chart

KalVista Pharmaceuticals Annual Data

Trend

Dec14

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

EBIT per Share

Get a 7-Day Free Trial

-1.76

-2.10

-2.54

-3.66

-3.63

KalVista Pharmaceuticals Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
EBIT per Share	Get a 7-Day Free Trial															-0.88	-0.85	-0.76	-0.82	-0.88

KalVista Pharmaceuticals EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

KalVista Pharmaceuticals's EBIT per Share for the fiscal year that ended in Apr. 2023 is calculated as

	EBIT per Share		(A: Apr. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-101.114	/	27.891
=	-3.63

KalVista Pharmaceuticals's EBIT per Share for the quarter that ended in Jan. 2024 is calculated as

	EBIT per Share		(Q: Jan. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-30.433	/	34.723
=	-0.88

EBIT per Share for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-3.30

KalVista Pharmaceuticals (STU:4XC1) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

KalVista Pharmaceuticals EBIT per Share Related Terms

Thank you for viewing the detailed overview of KalVista Pharmaceuticals's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

KalVista Pharmaceuticals (STU:4XC1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » KalVista Pharmaceuticals Inc (STU:4XC1) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

KALV:USA 4XC1:Germany

Address

55 Cambridge Parkway, Suite 901 East, Cambridge, MA, USA, 02142

Website

https://www.kalvista.com

KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States.

KalVista Pharmaceuticals (STU:4XC1) Headlines

No Headlines